PIN Pharma

PIN Pharma is a clinical-stage biotechnology company based in New York City that develops next-generation precision immunotherapies for the treatment of cancer. The company's lead product candidate, PIN-2, is a multi-epitope peptide-based immunotherapy designed to activate and direct the patient's immune system to recognize and destroy solid tumors. PIN Pharma's approach utilizes its proprietary platform to identify specific tumor-associated antigens, aiming to overcome the immunosuppressive environments that often render traditional checkpoint inhibitors ineffective. The company primarily focuses on high-unmet-need oncological indications, including recurrent ovarian cancer and other advanced solid malignancies. By combining precision targeting with potent immune activation, PIN Pharma seeks to provide more durable clinical responses for cancer patients.